Piritramide

Summary

Piritramide (CHEMBL559288) is a phase-3 clinical-stage small molecule (ATC N02AC03); indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N02AC03
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 430.6 Da · C27H34N4O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL559288
Name	Piritramide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9331
ATC	N02AC03
Molecular formula	C27H34N4O
Molecular weight	430.6
InChIKey	IHEHEFLXQFOQJO-UHFFFAOYSA-N

SMILES: C1CCN(CC1)C2(CCN(CC2)CCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4)C(=O)N

IUPAC name: 1-(3-cyano-3,3-diphenylpropyl)-4-piperidin-1-ylpiperidine-4-carboxamide

Also known as: Dipidolor, IDS-NP-013, Piritramida, Piritramide, R 3365, R-3365, PIRITRAMIDE

Patent coverage: 1,872 distinct patent families (8,148 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02314871	PHASE4	COMPLETED	Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
NCT02544282	PHASE4	COMPLETED	Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 6 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).